Resistance to cisplatin and paclitaxel does not affect the sensitivity of human ovarian cancer cells to antiprogestin-induced cytotoxicity

Latest research and treatment of advanced-stage epithelial ovarian cancer

(2013) Robert L. Coleman et al.   Nature Reviews Clinical Oncology

Glucocorticoid receptor signaling in health and disease

(2013) Mahita Kadmiel et al.   TRENDS IN PHARMACOLOGICAL SCIENCES

Mifepristone prevents repopulation of ovarian cancer cells escaping cisplatin-paclitaxel therapy

(2012) Carlos D Gamarra-Luques et al.   BMC CANCER

Minireview: Human Ovarian Cancer: Biology, Current Management, and Paths to Personalizing Therapy

(2012) Ignacio Romero et al.   ENDOCRINOLOGY

Resistance to Paclitaxel in a Cisplatin-Resistant Ovarian Cancer Cell Line Is Mediated by P-Glycoprotein

(2012) Britta Stordal et al.   PLoS One

Antiprogestin mifepristone inhibits the growth of cancer cells of reproductive and non-reproductive origin regardless of progesterone receptor expression

(2011) Chelsea R Tieszen et al.   BMC CANCER

Molecular pathogenesis and extraovarian origin of epithelial ovarian cancer—Shifting the paradigm

(2011) Robert J. Kurman et al.   HUMAN PATHOLOGY

Growth inhibition induced by antiprogestins RU-38486, ORG-31710, and CDB-2914 in ovarian cancer cells involves inhibition of cyclin dependent kinase 2

(2011) Alicia A. Goyeneche et al.   INVESTIGATIONAL NEW DRUGS

Analysis of p53 mutation status in human cancer cell lines: a paradigm for cell line cross-contamination

(2010) Hanna Berglind et al.   CANCER BIOLOGY & THERAPY

Genomic analysis of genetic heterogeneity and evolution in high-grade serous ovarian carcinoma

(2010) S L Cooke et al.   ONCOGENE

Resistance to cisplatin does not affect sensitivity of human ovarian cancer cell lines to mifepristone cytotoxicity

(2009) Elizabeth M Freeburg et al.   Cancer Cell International

Clinical utility of progesterone receptor modulators and their effect on the endometrium

(2009) Irving M Spitz   CURRENT OPINION IN OBSTETRICS & GYNECOLOGY

Investigational developments for the treatment of progesterone-dependent diseases

(2008) Carsten Möller et al.   EXPERT OPINION ON INVESTIGATIONAL DRUGS

Selective progesterone receptor modulators 1: use during pregnancy

(2008) Giuseppe Benagiano et al.   EXPERT OPINION ON PHARMACOTHERAPY